Second Sight Medical Products, Inc. (NASDAQ:EYES – Get Rating) executive Gregg Williams purchased 167,160 shares of the company in a trade that took place on Monday, May 23. The shares were purchased at an average price of $1.97 per share, for a total transaction of $329,305.20. Following the acquisition, the administrator now directly owns 10,861,456 shares of the company, valued at approximately $21,397,068.32. The acquisition was disclosed in a filing with the SEC, accessible via this hyperlink.

Gregg Williams also recently made the following trade(s):

• On Wednesday, May 18, Gregg Williams purchased 387,044 shares of Second Sight Medical Products. The stock was purchased at an average price of $1.66 per share, for a total transaction of $642,493.04.

EYES stock was down $0.23 during Wednesday’s trading, hitting $1.78. The company had a trading volume of 293,861 shares, compared to an average volume of 488,159. Second Sight Medical Products, Inc. has a 12-month low of $1.14 and a 12-month high of 7.64 $. The company has a 50-day simple moving average of $1.51 and a 200-day simple moving average of $1.63.

Second Sight Medical Products (NASDAQ:EYES – Get Rating) last released its quarterly results on Monday, March 28. The medical device company reported ($0.02) earnings per share for the quarter.

A number of hedge funds and other institutional investors have recently changed their positions in EYES. Renaissance Technologies LLC purchased a new stock position in Second Sight Medical Products during Q1 worth approximately $249,000. Vanguard Group Inc. increased its holdings in Second Sight Medical Products by 1.4% in the first quarter. Vanguard Group Inc. now owns 1,221,704 shares of the medical device company valued at $1,747,000 after acquiring an additional 17,164 shares during the period. Goldman Sachs Group Inc. increased its position in Second Sight Medical Products by 37.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 33,950 shares of the medical device company worth $55,000 after buying an additional 9,272 shares last quarter. State Street Corp increased its stake in shares of Second Sight Medical Products by 31.5% during the 4th quarter. State Street Corp now owns 79,694 shares of the medical device company worth $130,000 after buying an additional 19,100 shares during the period. Finally, LPL Financial LLC increased its stake in Second Sight Medical Products shares by 93.0% during the 4th quarter. LPL Financial LLC now owns 20,698 shares of the medical device company valued at $34,000 after buying an additional 9,971 shares last quarter. Institutional investors and hedge funds hold 9.09% of the company’s shares.

Separately, StockNews.com upgraded shares of Second Sight Medical Products to a “sell” rating in a Wednesday, March 30, research report.

Second Sight Medical Products Company Profile (Get a rating)

Second Sight Medical Products, Inc. develops, manufactures and markets implantable vision prostheses intended to provide artificial vision to people who are blind. It develops technologies to treat the visually impaired population. The Company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, intended to provide useful artificial vision to people who are blind due to a variety of causes, including glaucoma, diabetic retinopathy, optic nerve damage or disease, and eye damage.

See also

Receive daily news and reviews for Second Sight medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Second Sight Medical Products and related companies with MarketBeat.com’s FREE daily newsletter.